IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Should You Sell?

IPSEN (OTCMKTS:IPSEY)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $49.15, but opened at $46.50. IPSEN shares last traded at $46.50, with a volume of 190 shares traded.

Analysts Set New Price Targets

IPSEY has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, Barclays downgraded shares of IPSEN from an “equal weight” rating to an “underweight” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, IPSEN presently has an average rating of “Reduce”.

IPSEN Price Performance

The business’s 50 day moving average is $46.60 and its 200-day moving average is $46.76.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.